Keppra
Epileptic Encephalopathy
Beijing Pins Medical Co., LtdDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Epileptic Encephalopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- Zogenix, Inc. | Phase 3 | BB |
Elsunersen Praxis Precision Medicines | Phase 3 | B |
Nbi-827104 Neurocrine Biosciences | Phase 2 | CCC |
S230815 Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Stiripentol Biocodex | Phase 1 | CC |
Cannimed® 1:20 University of Saskatchewan | Phase 1 | CC |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →